Top Industry Leaders in the Nanobody Market
Latest Nanobody Companies Update
Nov 2023: A collaboration between Huma Therapeutics & Merck KGaA intends to inform and assist cancer patients in managing their course of therapy. Through the partnership, a Cross-Indication Disease Management Platform will be created using Huma's technology, providing patients receiving cancer treatments from Merck KGaA, Darmstadt, Germany, with access to a care pathway and educational resources. Launched in the UK in 2024, the Cross-Indication Disease Management Platform will assist patients suffering from urothelial carcinoma, a cancer that arises from urothelial cells lining the bladder, ureters, renal pelvis, and other organs. With US Food and Drug Administration (FDA) Class II 510(k) clearance and EU MDR Class IIb regulation, Huma will leverage its disease-agnostic Software as a Medical Device (SaMD) technology platform to enable the service.
The monoclonal antibody Dupixent from Sanofi and Regeneron has achieved success in a second phase 3 study for chronic obstructive pulmonary disease (COPD), making it the first biologic to treat the lung illness and the initial breakthrough in the indication in over ten years. Dupixent will have access to yet another huge market if COPD is approved. Dupixent is already on a juggernaut trajectory as a treatment for asthma, atopic dermatitis, and several other inflammatory disorders. The drug brought in $3.1 billion in the third quarter, a 33% rise year over year. The drug's revenues for the first nine months were $8.4 billion after the third quarter's success.
List of Nanobody Key companies in the market
- Sanofi (France)
- Merck KGaA (Germany)
- BIOCYTOGEN (US)
- Proteintech Group, Inc (US)
- Novartis AG (Switzerland)
- GenScript (US)
- Sensei Biotherapeutics, Inc (US)
- Beroni Group (Australia)
- ExeVir Bio (Belgium)
- Taisho Pharmaceutical Holdings Co., Ltd (Japan)
- DiosCURE Therapeutics SE (Germany)